Described herein are methods for the noninvasive immunization of a subject that involve alkyl glycosides. Also described herein are compositions, kits, and devices for the noninvasive immunization of a subject.
대표청구항▼
What is claimed is: 1. A method for increasing the penetration of a vaccine through the skin of a subject, comprising: (a) contacting the skin of the subject with a first composition comprising an effective amount of an alkyl glycoside, wherein the first composition is free of oil; and (b) contacti
What is claimed is: 1. A method for increasing the penetration of a vaccine through the skin of a subject, comprising: (a) contacting the skin of the subject with a first composition comprising an effective amount of an alkyl glycoside, wherein the first composition is free of oil; and (b) contacting the skin of the subject with a second composition comprising an effective amount of the vaccine, wherein the second composition is free of oil, whereby the amount of vaccine that penetrates the skin of the subject is greater after step (b) when compared to the amount of vaccine that is absorbed in the absence of step (a). 2. The method of claim 1, wherein the alkyl glycoside is nonionic. 3. The method of claim 1, wherein the alkyl group comprises from 6 to 24 carbons. 4. The method of claim 1, wherein the alkyl group comprises from 6 to 14 carbon atoms. 5. The method of claim 1, wherein the saccharide comprises erythrose, threose, ribose, arabinose, xylose, lyxose, allose, altrose, glucose, mannose, gulose, idose, galactose, talose, fructose, maltose, cellobiose, maltotriose, maltotetraose, sucrose, lactose, trehalose, raffinose, or a derivative or combination thereof. 6. The method of claim 1, wherein the linkage comprises a glycosidic linkage, a thioglycosidic linkage, an amide linkage, a ureide linkage, an ester linkage, or a combination thereof. 7. The method of claim 1, wherein the alkyl glycoside comprises a hydrophile-lipophile balance number in the range of about 10 to 20. 8. The method of claim 1, wherein the alkyl glycoside comprises an alkyl thiomaltoside, an alkyl thioglucoside, or an alkyl thiosucrose. 9. The method of claim 1, wherein the alkyl glycoside comprises hexyl-, heptyl-, octyl-, nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-, tetradecyl-, pentadecyl-, hexadecyl-, heptadecyl-, or octadecyl α-or β-D-maltoside; hexyl-, heptyl-, octyl-, nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-, tetradecyl-, pentadecyl-, hexadecyl-, heptadecyl-, or octadecyl α-or β-D-glucoside; hexyl-, heptyl-, octyl-, nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-, tetradecyl-, pentadecyl-, hexadecyl-, heptadecyl-, or octadecyl esters of sucrose; hexyl-, heptyl-, octyl-, dodecyl-, tridecyl-, or tetradecyl-β-D-thiomaltoside; heptyl-or octyl-1-thio-β-glucopyranoside; heptyl-or octyl-1-thio-β-D-glucopyranoside; a long chain aliphatic carbonic acid amide of a sucrose β-amino-alkyl ether; a derivative of palatinose or isomaltamine linked by an amide linkage to an alkyl chain; a derivative of isomaltamine linked by urea to an alkyl chain, a long chain aliphatic carbonic acid ureide of a sucrose β-amino-alkyl ether; or a long chain aliphatic carbonic acid amide of a sucrose β-amino-alkyl ether. 10. The method of claim 1, wherein the alkyl glycoside comprises a saccharide comprising maltose, sucrose, glucose, or a combination thereof linked to an alkyl group having from 6 to 14 carbon atoms by a glycosidic linkage. 11. The method of claim 1, wherein the alkyl glycoside has a concentration in the range of about 0.01% to 10%. 12. The method of claim 1, wherein the vaccine comprises a vectored-vaccine, a protein-based vaccine, a DNA-based vaccine, or a RNA-based vaccine. 13. The method of claim 1, wherein the vaccine comprises a vector. 14. The method of claim 13, wherein the vector comprises a viral vector. 15. The method of claim 13, wherein the vector comprises a bacterial vector. 16. The method of claim 13, wherein the vector comprises an E. coli vector. 17. The method of claim 13, wherein the vector comprises and expresses a nucleic acid molecule encoding a gene product. 18. The method of claim 17, wherein the nucleic acid molecule encodes an antigen. 19. The method of claim 17, wherein the nucleic acid molecule encodes one or more of: influenza hemaglutinin, influenza nuclear protein, influenza M2, tetanus toxin C-fragment, anthrax protective antigen, anthrax lethal factor, anthrax germination and outgrowth-associated protein, rabies glycoprotein, HBV surface antigen, HIV gp 120, HIV gp 160, human carcinoembryonic antigen, malaria CSP, malaria SSP, malaria MSP and malaria pfg. 20. The method of claim 17, wherein the nucleic acid molecule is exogenous or heterologous to the vector. 21. The method of claim 20, wherein the exogenous or heterologous nucleic acid molecule encodes an epitope. 22. The method of claim 20, wherein the exogenous or heterologous nucleic acid molecule encodes one or more antigens or a portion thereof from a pathogen of the subject or one or more epitopes from a pathogen of the subject. 23. The method of claim 20, wherein the exogenous or heterologous nucleic acid molecule encodes an immunomodulatory gene or a therapeutic gene. 24. The method of claim 23, wherein the immunomodulatory gene comprises a co-stimulator, a cytokine, a chemokines, or a combination thereof. 25. The method of claim 1, wherein the vaccine comprises a nucleic acid molecule that encodes a gene product that stimulates and/or modulates an immunological response. 26. The method of claim 1, wherein the vaccine comprises a nucleic acid molecule that translates an endogenous and/or exogenous nucleic acid molecule. 27. The method of claim 1, wherein the vaccine induces a systemic immune response against a pathogen or a neoplasm. 28. The method of claim 1, wherein the vaccine comprises a DNA/liposome complex. 29. The method of claim 1, wherein the vaccine is matched to or is a natural pathogen of the subject. 30. The method of claim 1, wherein the subject comprises a human. 31. The method of claim 1, wherein the alkyl glycoside and the vaccine are administered non-invasively. 32. The method of claim 1, wherein the alkyl glycoside and the vaccine are administered to the subject in the form of a patch, an ointment, a cream, a lotion, a drop, a spray, an aerosol, a sustained-release format, or a combination thereof. 33. The method of claim 1, wherein the alkyl glycoside and the vaccine are administered to the subject topically. 34. The method of claim 33, wherein upon topical administration to the subject, the vaccine penetrates the stratum corneum of the subject and reaches the dermal and epidermal layers of the subject. 35. The method of claim 1, wherein the alkyl glycoside and the vaccine are administered sequentially to the subject. 36. The method of claim 1, wherein the alkyl glycoside and the vaccine are administered concurrently to the subject. 37. The method of claim 1, wherein a second vaccine is administered invasively prior to step (a) and/or after step (b). 38. The method of claim 1, wherein prior to step (a), brushing the skin with an abrasive. 39. A method for enhancing, inducing, or potentiating an immune response or a therapeutic response in a subject, comprising: (a) contacting skin cells of the subject with a first composition comprising an effective amount of an alkyl glycoside, wherein the first composition is free of oil; and (b) contacting the skin cells of the subject with a second composition comprising an effective amount of a vaccine, wherein the second composition is free of oil. 40. The method of claim 39, wherein the immune response is greater after step (b) when compared to the immune response in the absence of step (a), thereby resulting in an enhanced immune response in a subject. 41. The method of claim 40, wherein the immune response is a systemic immune response. 42. The method of claim 39, wherein the contacting step is in vivo.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (108)
Muzyczka Nicholas (Stony Brook NY) Hermonat Paul L. (Bethesda MD) Berns Kenneth I. (Mamaroneck NY) Samulski Richard J. (Princeton NJ), AAV transduction vectors.
Gregory Richard J. ; Armentano Donna ; Couture Larry A. ; Smith Alan E., Adenoviral vectors for gene therapy containing deletions in the adenoviral genome.
Gregory Richard J. (Carlsbad CA) Armentano Donna (Watertown MA) Couture Larry A. (Framingham MA) Smith Alan E. (Wellesley MA), Adenovirus vector for gene therapy.
Wickham Thomas J. ; Falck-Pedersen Erik ; Roelvink Petrus W. ; Bruder Joseph T. ; Gall Jason ; Kovesdi Imre, Chimeric adenoviral fiber protein and methods of using same.
Curiel David T. (Chapel Hill NC) Birnstiel Max L. (Vienna ATX) Cotten Matthew (Vienna ATX) Wagner Ernst (Langenzersdorf ATX) Zatloukal Kurt (Vienna ATX) Plank Christian (Vienna ATX) Oberhauser Berndt, Composition for introducing nucleic acid complexes into higher eucaryotic cells.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Wolff Jon A. (Madison WI) Duke David J. (Salem OR) Felgner Philip L. (Rancho Santa Fe CA), Expression of exogenous polynucleotide sequences cardiac muscle of a mammal.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon Asher (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert Wallace (Davis CA) Carson Dennis A. (Del Mar CA), Generation of antibodies through lipid mediated DNA delivery.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Zygraich Nathan (Brussels BE) Huygelen Constant (Huldenberg BE), Live brovine adenovirus vaccines, preparation thereof and method of vaccination using them.
Gristina Anthony G. (Reston VA) Myrvik Quentin N. (Caswell Beach NC), Method and compositions for the direct concentrated delivery of passive immunity.
Smith Gale Eugene ; Volvovitz Franklin ; Wilkinson Bethanie Eident ; Hackett Craig Stanway, Method for producing influenza hemagglutinin multivalent vaccines using baculovirus.
Finer Mitchell H. ; Roberts Margo R. ; Dull Thomas J. ; Zsebo Krisztina M. ; Qin Lu ; Farson Deborah A., Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells.
Papahadjopoulos Demetrios P. (78 Heathwood Williamsville NY 14221) Szoka ; Jr. Francis C. (375 Leroy Ave. Buffalo NY 14214), Method of encapsulating biologically active materials in lipid vesicles.
Papahadjopoulos Demetrios P. (78 Heathwood Williamsville NY 14221) Szoka ; Jr. Francis C. (375 Leroy Ave. Buffalo NY 14214), Method of encapsulating biologically active materials in lipid vesicles.
Szoka ; Jr. Francis C. (76 Summit St. Waltham MA 02154) Papahadjopoulos Demetrios P. (3170 Condit St. Lafayette CA 94549), Method of inserting DNA into living cells.
Gristina Anthony G. (11605 Deer Forest Rd. Reston VA 22094) Myrvik Quentin N. (404 Palmetto Dr. Caswell Beach NC 28465), Methods and compositions for the direct concentrated delivery of passive immunity.
Carson Dennis A. (Del Mar CA) Raz Eyal (San Diego CA), Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleoti.
Carson Dennis A. ; Raz Eyal ; Howell Meredith L., Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptide.
Metzger Jorg (Tubingen DEX) Wiesmuller Karl-Heinz (Tubingen DEX) Jung Gunther (Tubingen DEX), N-acyl-S-(2-hydroxyalkyl) cysteines, their preparation and their use as intermediates for the preparation of synthetic i.
Paoletti Enzo (Delmar NY) Perkus Marion E. (Altamont NY) Taylor Jill (Albany NY) Tartaglia James (Schenectady NY) Norton Elizabeth K. (Latham NY) Riviere Michel (Ecully FRX) de Taisne Charles (Lyons , NYVAC vaccinia virus recombinants comprising heterologous inserts.
De-chu C. Tang ; Donald H. Marks ; David T. Curiel ; Zhongkai Shi ; Kent Rigby van Kampen, Noninvasive genetic immunization, expression products therefrom and uses thereof.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Backstrom Kjell Goran Erik,SEX ; Dahlback Carl Magnus Olof,SEX ; Edman Peter,SEX ; Johansson Ann Charlotte Birgit,SEX, Processes for preparing compositions for inhalation.
Elliot James I. (Ottawa CAX) Timbers Gordon E. (Nepean CAX) Modler H. Wayne (Kemptville CAX) Allen Robert W. (Carp CAX), Production of purified porcine immunoglobulins.
Mittal Suresh K.,CAX ; Graham Frank L.,CAX ; Prevec Ludvik,CAX ; Babiuk Lorne A.,CAX, Recombinant protein production in bovine adenovirus expression vector system.
Ertl Hildegund C. J. (Villanova PA) Wilson James M. (Gladwyne PA), Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier.
Bebbington, Christopher Robert; Kingsman, Susan Mary; Uden, Mark; Kingsman, Alan John; Mitrophanos, Kyriacos, Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site.
Tibbetts Clark (Nashville TN) Larsen Pamela L. (Cambridge MA) Jones Stephen N. (Nashville TN) McGrane Mary M. (Cleveland Heights OH), Transcriptional control element adapted for regulation of gene expression in animal cells.
Paoletti Enzo ; Perkus Marion E. ; Taylor Jill ; Tartaglia James ; Norton Elizabeth K. ; Riviere Michel,FRX ; de Taisne Charles,FRX ; Limbach Keith J. ; Johnson Gerard P. ; Pincus Steven E. ; Cox Wil, Trova fowl pox virus recombinants comprising heterologous inserts.
Rose John K. (Solana Beach CA) Moss Bernard (Bethesda MD) Yilma Tilahun (Pullman WA) Mackett Michael (Rusholme GB2), Vaccine for vesicular stomatitis virus.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.